DETAILS

Drug ID	DDPD00227
Drug Name	Lovastatin
Molecular Weight	404.5396
Molecular Formula	C24H36O5
CAS Number	75330-75-5
SMILES	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
External Links
	DRUGBANK	DB00227
	T3DB	T3D4787
	PubChem Compound	53232
	PDR	1923
	Drugs.com	Drugs.com Drug Page

Property Name	Property Value	Unit	Raw Value	Raw Unit	Reference
Log P	4.08	-	4.08	-	'MSDS'
Boiling Point	559.2	℃	559.2	℃	Chemspider
Melting Point	174.5	℃	174.5	℃	'MSDS'
Water Solubility	0.4	mg/L	0.0004	mg/ml	'MSDS'
pKa	13.49	-	13.49	-	Chuong M. et al. (2013). International Journal of Applied Pharmaceutics.

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Factor	Reference
AUC	33.5	ng.h/ml	14-53	ng.h/ml	PO, oral;		DRUGBANK
Bioavailability	5.0	%	≤5	%	PO, oral;		The Pharmacological Basis of Therapeutics
C Max	3.0	ng/ml	3.013	ng/ml			DRUGBANK
C Max	2.5	ng/ml	1.04-4.03	ng/ml	PO, oral;		DRUGBANK
C Max	41.0	ngEq/ml	41±6	ngEq/ml	PO, oral; Active metabolite;		The Pharmacological Basis of Therapeutics
C Max	50.0	ngEq/ml	50±8	ngEq/ml	PO, oral; Active metabolite;		The Pharmacological Basis of Therapeutics
T Max	3.4	h	3.36	h			DRUGBANK
T Max	2.0	h	2.0±0.9	h	PO, oral; Active metabolite;		The Pharmacological Basis of Therapeutics
T Max	3.1	h	3.1±2.9	h	PO, oral; Active metabolite;		The Pharmacological Basis of Therapeutics
Clearance	0.68	L/h/kg	4.3-18.3	ml/min/kg	hydrolysis;	RD, renal impairment, Renal disease，including uremia ↓ ;	The Pharmacological Basis of Therapeutics
Half-life	13.4	h	13.37	h			DRUGBANK
Half-life	1.9	h	0.7-3	h	elimination half-life;		DRUGBANK
Half-life	2.5	h	1-4	h			The Pharmacological Basis of Therapeutics
Toxicity LD50	15000.0	mg/m2	>15	g/m2			DRUGBANK
Toxicity LD50	1000.0	mg/kg	>1000	mg/kg	PO, oral; mouse;		T3DB
Eliminate Route	10.0	%	10	%	Urinary excretion; PO, oral; Male, men;		DRUGBANK
Eliminate Route	83.0	%	83	%	Faeces excretion; PO, oral; Male, men;		DRUGBANK
Eliminate Route	10.0	%	10	%	Urinary excretion; Unchanged drug;		The Pharmacological Basis of Therapeutics
Protein Binding	95.0	%	>95	%	plasma proteins; human, homo sapiens;		DRUGBANK
Protein Binding	95.0	%	>95	%			The Pharmacological Basis of Therapeutics

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Brand Name	Component	Reference
Max dose for children	40.0	mg/day	40	mg/day	Tablet,PO，oral	Altoprev	lovastatin	PDR
Max dose for adolescents	40.0	mg/day	40	mg/day	Tablet,PO，oral	Altoprev	lovastatin	PDR
Max dose for adults	80.0	mg/day	80	mg/day	Tablet,PO，oral	Altoprev	lovastatin	PDR
Max dose for adults	60.0	mg/day	60	mg/day	Tablet,PO，oral	Altoprev	lovastatin	PDR
Max dose for adults	20.0	mg/day	20	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for adults	40.0	mg/day	40	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for adults	20.0	mg/day	20	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for elderly	80.0	mg/day	80	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for elderly	60.0	mg/day	60	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for elderly	20.0	mg/day	20	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for elderly	40.0	mg/day	40	mg/day	PO, oral	Altoprev	lovastatin	PDR
Max dose for elderly	20.0	mg/day	20	mg/day	PO, oral	Altoprev	lovastatin	PDR

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1